A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients.
All News
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.
A pilot trial has shown a thrombopoietin receptor agonist, eltrombopag (Promacta), to be effective in connective tissue disease-related (CTD), refractory immune thrombocytopenia (ITP).
Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com
EULAR has established guidance on best practices for delivering patient education in physical activity and self-management of pain during transitional care in rheumatology.
An epidemiologic assessment of the prevalence of autoimmune diseases in the United States (US) finds that nearly 5% of the population has an autoimmune disorder, twice as many in women compared to men.
The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential alternative to zoster vaccination.
A Modifiable Vascular Risk in SLE
Atherosclerosis progression was more than twice as common in younger people with SLE than in healthy controls in a prospective study from Greece, but the rate difference narrowed substantially with sustained SLE remission and conventional cardiovascular risk factor management.


